Scholarlink

<p>Illicit drug use has been increasing rapidly in Sub-Saharan Africa in the past decade. However, until recently HIV prevention has largely ignored people who inject drugs and medications to treat opioid use disorder (MOUD) were largely absent. This paper reports results of a pilot intervention that integrated buprenorphine into a harm-reduction drop-in-center for people with opioid use disorder (OUD) in Kampala, Uganda. We collected implementation outcomes and changes in self-reported drug use after buprenorphine initiation. We conducted qualitative interviews with a subset of 14 participants who had initiated buprenorphine. Sixty-two participants were screened for OUD, of whom 57 were eligible for buprenorphine; of those, 55 initiated buprenorphine and 39 were still taking buprenorphine at three months (70.9%). Participants reported significant reductions in opioid use, marijuana and cocaine at 3-month follow up (<i>p</i> &lt; 0.001, <i>p</i> = 0.006 <i>p</i> &lt; 0.001 respectively). Integration of buprenorphine into DICs was successful and removed many barriers patients face in accessing MOUD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Feasibility, Acceptability, and Preliminary Efficacy of a Pilot Study To Integrate Buprenorphine into a Harm-reduction Drop-in-Center in Kampala, Uganda

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月1日

查看全文
  • Julia Dickson-Gomez,
  • Sergey Tarima,
  • Wamala Twaibu,
  • Dan Katende,
  • Latifah Kyeswa,
  • Laura Glasman,
  • Arthur Kiconco,
  • Sarah Krechel,
  • Bryan Johnston,
  • Moses Ogwal,
  • Brian Byamah Mutamba,
  • Peter Mudiope,
  • Stella Alamo,
  • Rhoda Wanyenze,
  • Geofrey Musinguzi

摘要

Illicit drug use has been increasing rapidly in Sub-Saharan Africa in the past decade. However, until recently HIV prevention has largely ignored people who inject drugs and medications to treat opioid use disorder (MOUD) were largely absent. This paper reports results of a pilot intervention that integrated buprenorphine into a harm-reduction drop-in-center for people with opioid use disorder (OUD) in Kampala, Uganda. We collected implementation outcomes and changes in self-reported drug use after buprenorphine initiation. We conducted qualitative interviews with a subset of 14 participants who had initiated buprenorphine. Sixty-two participants were screened for OUD, of whom 57 were eligible for buprenorphine; of those, 55 initiated buprenorphine and 39 were still taking buprenorphine at three months (70.9%). Participants reported significant reductions in opioid use, marijuana and cocaine at 3-month follow up (p < 0.001, p = 0.006 p < 0.001 respectively). Integration of buprenorphine into DICs was successful and removed many barriers patients face in accessing MOUD.